Globe Life IncNYSE: GL
Financials · Life & Health Insurance
$171.01
-0.14%
Vol: 724K
Research Digest
Friday, June 19, 2026
Globe Life hits all-time high of $169.58 on June 15 following favorable Mad Money mention and analyst upgrades, with Truist raising price target to $185 after Q1 EPS rose 13% and full-year guidance lifted.
Globe Life (GL) reached an all-time high of $169.58 on June 15, 2026, propelled by a favorable Mad Money mention and building analyst momentum. In Q1 2026, the company reported net operating income per share of $3.43, up 12% year-over-year, and raised full-year 2026 EPS guidance to $15.40-$15.90 (up $0.35 at midpoint). Life net sales grew 6% and health net sales surged 58% year-over-year, while book value per share rose 19% to $77.03. Truist Securities raised its price target to $185 from $180 citing increased 2026 EPS estimates. The company repurchased 1.4 million shares at an average of $141.24 during Q1. The stock's 7-day return was 6.13% and 90-day return was 19.37%, with the next earnings report due July 29.
Previous Market Intelligence
13 daysJun 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 17No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 16No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Globe Life CFO Thomas Kalmbach sold an additional $1.86M in shares on May 20, bringing total CFO insider sales to over $6M this month as stock fell 4.8% on May 19.Negative▶
Globe Life CFO Thomas Kalmbach sold 11,903 shares for $1.86M on May 20, 2026, following a May 8-11 sale of 27,427 shares worth $4.19M (after exercising 35,000 options at $98.32). Shares fell 4.8% on May 19 to $149.87 after recently hitting an all-time high of $156.69 on May 6. The insider sales come after Q1 2026 revenue grew 5.4% to $1.56B though EPS of $3.43 missed the $3.48 estimate; management raised full-year guidance to $15.40-$15.90 per share. Analyst consensus is Buy with $174.73 price target from 11 analysts, with Truist citing double-digit operating EPS growth and robust health premium expansion.
May 20Globe Life CFO and Co-CEOs sell ~$10M in stock near all-time highs as shares pull back 4.8%Mixed▶
Globe Life saw heavy insider selling in May 2026: Co-Chairman & CEO Frank Svoboda sold 15,000 shares for $2.30M on May 6; Co-Chairman & CEO James Matthew Darden sold 22,019 shares for $3.39M; and EVP & CFO Thomas Kalmbach sold 27,427 shares for $4.19M on May 8 and 11. The sales occurred near an all-time high of $156.69 reached May 6. On May 19, shares fell 4.8% to $149.87. Globe Life recently reported Q1 2026 revenue of $1.56B (+5.4% YoY) and raised full-year EPS guidance to $15.40-$15.90, supported by strong health premium growth. The company previously raised its quarterly dividend to $0.33 per share, payable May 1, 2026.
May 19Globe Life CFO Thomas Kalmbach sold $4.19M in shares (27,427 shares at $151-$154) on May 8/11 as stock hit all-time high near $156.69Mixed▶
Globe Life CFO Thomas Kalmbach disclosed sales of 27,427 shares worth $4.19M on May 8 and 11, 2026, at prices of $151.38-$152.47, after exercising options at $98.32. The transactions occurred as GL traded near its 52-week high of $156.69. Earlier in the month, Co-Chairmen Frank Svoboda and James Matthew Darden also sold shares worth $2.3M and $3.4M respectively. The insider sales follow a strong Q1 earnings call featuring double-digit operating EPS growth, robust health premium expansion, and raised operating EPS guidance. Globe Life raised its quarterly dividend to $0.33 per share payable May 1, 2026, and added two new directors. TipRanks AI rates GL as Outperform despite recent insider activity.
May 18Globe Life CFO Thomas Kalmbach sold 27,427 shares worth $4.19M on May 8 and 11 near the stock 52-week high of $156.69.Mixed▶
Globe Life EVP & CFO Thomas Kalmbach sold 27,427 shares worth over $4.19 million at $151-$154 per share on May 8 and 11, 2026, disclosed in a Form 4 SEC filing. The transactions came near the stock 52-week high of $156.69 (closed at $154.91). Earlier in May, Globe Life had reported Q1 2026 revenue up 5.4% YoY to $1.56 billion and raised full-year EPS guidance to $15.40-$15.90, supported by strong health premium growth and buybacks. The company also paid a quarterly dividend of $0.33/share on May 1. Analyst sentiment remains constructive following the Q1 beat and guidance hike.
May 15Globe Life insiders dump $9.8M+ in stock (May 8-12): CFO sells $4.2M, CEO Svoboda $2.3M, Co-CEO Darden $3.4M near 52-week highMixed▶
A wave of insider sales at Globe Life hit the tape in early May 2026. CFO Thomas Kalmbach sold 27,427 shares for ~$4.19M at $151-$154 on May 8 and 11 (after exercising 35,000 options at $98.32). Co-Chairman & CEO Frank Svoboda sold 15,000 shares for ~$2.30M, and Co-Chairman & CEO James Matthew Darden sold 22,019 shares for ~$3.39M — totaling more than $9.8M of insider selling near the 52-week high of $156.69. The selling follows Q1 2026 results showing revenue +5.4% YoY to $1.56B and a raised FY26 EPS guide of $15.40-$15.90 driven by health-premium growth and buybacks. Globe Life also raised its quarterly dividend to $0.33 (paid May 1). Risk: cluster of top-officer sales at peak valuation is a yellow flag despite operationally strong Q1.
May 14Globe Life CFO sells $4.2M in shares as company reports strong Q1 2026 with EPS up to $3.39 and raised full-year guidanceMixed▶
Globe Life's EVP & CFO Thomas Kalmbach sold 27,427 shares worth over $4.19 million at prices around $151-$154 per share on May 8 and 11, 2026, drawing attention as recent insider activity. Earlier, the company reported Q1 2026 net income of $3.39 per diluted share (vs. $3.01 prior year) and net operating income of $3.43 (vs. $3.07), with revenue up 5.4% YoY to $1.56 billion. Globe Life raised its full-year 2026 EPS guidance to $15.40-$15.90, an increase of $0.35 at the midpoint. Direct-to-Consumer life underwriting margin rose 15% and United American health net sales jumped from $28M to ~$62M. The company repurchased 1.4 million shares for $203 million in the quarter and dual-listed on NYSE Texas. Consensus rating is Buy from 11 analysts with a 12-month target of $167.27. Risks include insider sale optics and exposure to underwriting cycles.
May 13Globe Life CFO Thomas Kalmbach sold ~27,400 shares for roughly $4.2 million across May 8 and May 11, while co-CEOs Svoboda and Darden together unloaded $5.7M after the stock hit an all-time high of $156.69.Negative▶
Globe Life saw a cluster of large insider sales in early May. CFO Thomas Kalmbach sold 11,790 shares at $152.02 on May 8 ($1.79M) and another 15,637 shares at $153.65 on May 11 ($2.40M). Co-Chairman/CEO Frank Svoboda sold 15,000 shares for $2.30M and Co-Chairman/CEO James Matthew Darden sold 22,019 shares for $3.39M. The selling came right after the stock hit an all-time high of $156.69 on May 6. Q1 2026 revenue rose 5.4% YoY to $1.56 billion and the company raised full-year EPS guidance to $15.40-$15.90 on strong health premium growth; a $0.33 quarterly dividend was declared, payable July 31. Risk: concentrated insider selling at peak prices can pressure sentiment and may invite renewed short-seller scrutiny.
May 12Globe Life shares hit an all-time high of $156.69 on May 6, 2026, after Q1 results and a raised FY2026 EPS guide to $15.40-$15.90.Mixed▶
Globe Life shares set an all-time high of $156.69 on May 6 following the company's Q1 2026 print: revenue rose 5.4% YoY to $1.56B, though EPS of $3.43 narrowly missed the $3.48 consensus. Management raised full-year guidance to $15.40-$15.90 per share on strong health premium growth and continued buybacks. Truist raised its PT to $185 from $180 with an updated FY26 EPS estimate of $15.60. Bear case: top insiders sold meaningful blocks of stock at the highs — Co-Chairman/CEO Frank Svoboda sold 15,000 shares (~$2.3M) and Co-Chairman/CEO James Matthew Darden sold 22,019 shares (~$3.4M).
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| AFLAFLAC | $115.31 | -0.80% | +2.7% | 15.9x | 0.60 | $61.5B |
| METMETLIFE | $85.65 | -0.23% | +6.5% | 8.2x | 0.78 | $57.9B |
| PRUPRUDENTIAL | $106.68 | -0.31% | +6.3% | 7.7x | 0.84 | $39.2B |
| PFGPRINCIPAL | $109.59 | -0.58% | +3.9% | 10.9x | 0.89 | $23.9B |
| GLGLOBE | $171.01 | -0.14% | +2.8% | 10.8x | 0.47 | $14.0B |
| BRK.BBERKSHIRE | $488.32 | -0.60% | +2.6% | 23.6x | 0.61 | $1.10T |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.